Trials / Completed
CompletedNCT02279641
RDEA3170 and Allopurinol Combination Study in Gout Subjects
A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Ardea Biosciences, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDEA3170 10 mg | |
| DRUG | allopurinol 300 mg |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-04-06
- Completion
- 2015-09-11
- First posted
- 2014-10-31
- Last updated
- 2017-12-20
- Results posted
- 2017-12-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02279641. Inclusion in this directory is not an endorsement.